(Q37387960)

20 August 2017

1 reference

title

Immunosuppression followed by immunomodulation (English)

1 reference

20 August 2017

1 reference

Mike Boggild

1

1 reference

20 August 2017

publication date

1 February 2009

1 reference

Journal of the Neurological Sciences

20 August 2017

published in

1 reference

20 August 2017

volume

277 Suppl 1

1 reference

20 August 2017

page(s)

S50-4

1 reference

Treatment of rheumatoid arthritis.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Rationale for early intervention with immunomodulatory treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Fertility in patients with multiple sclerosis: current knowledge and future perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Long-term experience with induction treatment regimens in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970014-0

10.1016/S0022-510X(09)70014-0

7 January 2021

Identifiers

DOI

1 reference

release_gxbq75zn75cohbqi6asnwn52cu

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gxbq75zn75cohbqi6asnwn52cu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference